[{"Assets_0_Q2_USD":417830000.0,"CommonStockSharesOutstanding_0_Q2_shares":145858900.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-29210000.0,"NetIncomeLoss_1_Q2_USD":-14624000.0,"NetIncomeLoss_2_Q2_USD":-12828000.0,"StockholdersEquity_0_Q2_USD":260052000.0,"Ticker":"HALO","CIK":"1159036","name":"HALOZYME THERAPEUTICS, INC.","OfficialName":"Halozyme Therapeutics Inc. Common Stock","form":"10-Q","period":"20190630","fy":"2019.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"5856719603.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20190806"}]